MX2012000577A - Compuestos de amino spiro apropiados para el tratamiento entre otras cosas de trastornos de sueño y adiccion a los farmacos. - Google Patents

Compuestos de amino spiro apropiados para el tratamiento entre otras cosas de trastornos de sueño y adiccion a los farmacos.

Info

Publication number
MX2012000577A
MX2012000577A MX2012000577A MX2012000577A MX2012000577A MX 2012000577 A MX2012000577 A MX 2012000577A MX 2012000577 A MX2012000577 A MX 2012000577A MX 2012000577 A MX2012000577 A MX 2012000577A MX 2012000577 A MX2012000577 A MX 2012000577A
Authority
MX
Mexico
Prior art keywords
treatment
inter alia
sleep disorders
compounds suitable
amino compounds
Prior art date
Application number
MX2012000577A
Other languages
English (en)
Inventor
Luigi Piero Stasi
Lucio Rovati
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Publication of MX2012000577A publication Critical patent/MX2012000577A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con un compuesto spiro-amino de la Fórmula (VI) en donde m es 1 ó 2 ó 3, n es 1 ó 2, R se selecciona de un anillo aromático de 5 ó 6 miembros y un anillo heteroaromático de 5 ó 6 miembros que comprende de 1 a 3 heteroátomos seleccionados de S, O y N, tal anillo es substituido con uno o dos sustituyentes seleccionados del grupo que consiste de alquilo(C1-C3), halógeno, cicloalquiloxi(C3-C5), alquilcarbonilo(C1-C3), fenilo opcionalmente substituido con uno o más átomos de halógeno, un heterociclo de 5 ó 6 miembros que comprende por lo menos un átomo de nitrógeno; P es un sustituyente Q o COQ, en donde Q es seleccionado del grupo que consiste de fenilo, piridilo, pirimidilo, quinolilo, isoquinolilo, quinoxalilo, benzofuranilo, imidazotriazolilo, tal Q es opcionalmente substituido con uno o más sustituyentes seleccionados del grupo que consiste de alquilo(C1-C3), halógeno, trifluorometilo, carbamido, metilcarbamido, carboxi; metilcarboxi o una sal farmacéuticamente aceptable del mismo.
MX2012000577A 2009-07-15 2010-07-15 Compuestos de amino spiro apropiados para el tratamiento entre otras cosas de trastornos de sueño y adiccion a los farmacos. MX2012000577A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425285A EP2275421A1 (en) 2009-07-15 2009-07-15 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
PCT/EP2010/060206 WO2011006960A1 (en) 2009-07-15 2010-07-15 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction

Publications (1)

Publication Number Publication Date
MX2012000577A true MX2012000577A (es) 2012-05-08

Family

ID=41820711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000577A MX2012000577A (es) 2009-07-15 2010-07-15 Compuestos de amino spiro apropiados para el tratamiento entre otras cosas de trastornos de sueño y adiccion a los farmacos.

Country Status (12)

Country Link
US (1) US8859608B2 (es)
EP (2) EP2275421A1 (es)
JP (1) JP5814917B2 (es)
KR (1) KR101736424B1 (es)
CN (1) CN102471314B (es)
AU (1) AU2010272548B2 (es)
BR (1) BR112012001031A8 (es)
CA (1) CA2768329C (es)
ES (1) ES2537658T3 (es)
MX (1) MX2012000577A (es)
RU (1) RU2562609C2 (es)
WO (1) WO2011006960A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1008827B (zh) 1987-05-01 1990-07-18 霍蒂夫股份公司霍夫曼兄弟公司 挡土罩
EP2484674A1 (en) * 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
RU2565596C2 (ru) 2011-07-04 2015-10-20 Роттафарм Биотек С.Р.Л. Производные циклических аминов в качестве антагонистов рецептора ер4
ITMI20112329A1 (it) * 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
CN104610129B (zh) * 2015-01-08 2017-07-18 爱斯特（成都）生物制药有限公司 一种手性2‑取代基‑4‑哌啶酮‑1‑羧酸叔丁酯的合成方法
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
EP3676261B1 (en) 2017-09-01 2024-12-18 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN116583502A (zh) * 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1286141B1 (it) 1996-07-02 1998-07-07 Rotta Research Lab Derivati diammidici dell'acido antranilico ad attivita' antigastrinica procedimento per la loro preparazione e loro uso farmaceutico.
CZ20032990A3 (cs) 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US20090176789A1 (en) * 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
CL2007002809A1 (es) * 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
TW200833328A (en) * 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
ES2351079T3 (es) * 2007-05-14 2011-01-31 Actelion Pharmaceuticals Ltd. Derivados de 2-ciclopropil-tiazol.
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
BRPI0908096A2 (pt) * 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano

Also Published As

Publication number Publication date
RU2562609C2 (ru) 2015-09-10
RU2012105284A (ru) 2013-08-20
WO2011006960A1 (en) 2011-01-20
EP2454252A1 (en) 2012-05-23
KR20120038487A (ko) 2012-04-23
CA2768329A1 (en) 2011-01-20
AU2010272548A1 (en) 2012-02-23
EP2275421A1 (en) 2011-01-19
JP5814917B2 (ja) 2015-11-17
US20120115882A1 (en) 2012-05-10
CN102471314B (zh) 2015-05-13
EP2454252B1 (en) 2015-03-04
AU2010272548B2 (en) 2013-08-22
KR101736424B1 (ko) 2017-05-29
ES2537658T3 (es) 2015-06-10
US8859608B2 (en) 2014-10-14
CA2768329C (en) 2017-03-07
CN102471314A (zh) 2012-05-23
JP2012532916A (ja) 2012-12-20
BR112012001031A2 (pt) 2016-11-22
BR112012001031A8 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
JO3114B1 (ar) مركبات بيريدازينون
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
MY169179A (en) Novel piperidine compound or salt thereof
IN2014DN03063A (es)
JO2791B1 (en) Acid secretion inhibitor
SI2751083T1 (en) Quinolone compound
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
MX2014015501A (es) Carboxamidas heterociclicas fungicidas.
JP2013509392A5 (es)
EP2597088A4 (en) P2X4 Receptor Antagonists
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
JP2016516699A5 (es)
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
MX2016008536A (es) Derivados de fluoro-naftilo.
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ROTTAPHARM BIOTECH S.R.L.

FG Grant or registration